A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia 1 (MCL1)
inhibitor, in patients with relapsed/refractory hematologic malignancies. The purpose of this
study is to define the dosing schedule, maximally tolerated dose and/or estimate the optimal
biological dose to be used in subsequent development of PRT1419.